Epigenetic-Targeted Treatments for H3K27M-Mutant Midline Gliomas

Victor M. Lu, David J. Daniels

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Diffuse intrinsic pontine glioma (DIPG) is a lethal midline brainstem tumor that most commonly occurs in children and is genetically defined by substitution of methionine for lysine at site 27 of histone 3 (H3K27M) in the majority of cases. This mutation has since been shown to exert an influence on the posttranslational epigenetic landscape of this disease, with the loss of trimethylation at lysine 27 (H3K27me3) the most common alteration. Based on these findings, a number of drugs targeting these epigenetic changes have been proposed, specifically that alter histone trimethylation, acetylation, or phosphorylation. Various mechanisms have been explored, including inhibition of H327 demethylase and methyltransferase to target trimethylation, inhibition of histone deacetylase (HDAC) and bromodomain and extraterminal (BET) to target acetylation, and inhibition of phosphatase-related enzymes to target phosphorylation. This chapter reviews the current rationales and progress made to date in epigenetically targeting DIPG via these mechanisms.

Original languageEnglish (US)
Title of host publicationAdvances in Experimental Medicine and Biology
PublisherSpringer
Pages73-84
Number of pages12
DOIs
StatePublished - 2021

Publication series

NameAdvances in Experimental Medicine and Biology
Volume1283
ISSN (Print)0065-2598
ISSN (Electronic)2214-8019

Keywords

  • Acetylation
  • BET
  • Demethylase
  • Diffuse intrinsic pontine glioma
  • DIPG
  • DMG
  • H3 K27M
  • HDAC
  • Phosphorylation
  • Trimethylation

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Epigenetic-Targeted Treatments for H3K27M-Mutant Midline Gliomas'. Together they form a unique fingerprint.

Cite this